← All trials
NCT03374800
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2018
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 4800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- National Health and Medical Research Council, AustraliaCollaborator
- Australian and New Zealand Intensive Care Society Clinical Trials GroupCollaborator
- Canadian Critical Care Trials GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.